THC, Amphetamine, Morphine & Methadone Monoclonal Antibodies for Competitive LFA & ELISA Drug Test IVD Development
Drugs of abuse (DOA) antibodies are monoclonal antibodies specifically engineered for competitive inhibition immunoassay formats used in urine drug screening tests. Unlike protein biomarker detection — which uses sandwich immunoassay with two antibodies binding the large analyte simultaneously — drug screening targets small-molecule analytes (MW <500 Da) with a single antigenic epitope per molecule. This makes sandwich formats impossible: competitive inhibition is the universal approach for small-molecule drug detection in immunoassay. In a competitive LFA or ELISA, free drug in the urine sample competes directly with drug-protein conjugate (immobilized on the nitrocellulose membrane or coated on the plate) for a limited supply of anti-drug antibody. When drug concentration exceeds the assay cutoff, most antibody molecules are occupied by free drug, reducing binding to the membrane conjugate and generating a visible result (faint or absent test line in LFA). This inverse signal relationship is the immunological basis of all commercial DOA rapid test cassettes and dipsticks.
The global drug testing market is driven by regulatory mandates for workplace safety drug testing, clinical toxicology screening in emergency departments and pain management clinics, forensic and criminal justice drug testing, and drug treatment program compliance monitoring. The U.S. Substance Abuse and Mental Health Services Administration (SAMHSA) defines the standard 5-panel drug test — covering marijuana/THC, cocaine, opiates, amphetamines, and PCP — which is mandated for U.S. federal workplace drug testing programs and widely adopted internationally. The EU workplace drug testing landscape is governed by national regulations and EN 15964 standard, while Asian markets — particularly South Korea, Japan, and Southeast Asia — have their own DOA testing mandates focusing on methamphetamine, cannabis, and opioids.
Sekbio's drugs of abuse antibody panel covers four major drug classes commonly included in expanded DOA rapid test panels: THC (Δ9-tetrahydrocannabinol, cannabis), AMP (amphetamine), MOP (morphine/opiates), and MTD (methadone). Each antibody is a murine monoclonal antibody raised against the respective drug hapten conjugated to a carrier protein, using hybridoma technology to generate high-affinity, high-specificity anti-drug antibodies. These antibodies are validated for competitive LFA (lateral flow assay) development — the dominant platform for point-of-care and workplace drug screening rapid tests — and for competitive ELISA for laboratory-based quantitative drug panel testing. Sekbio's DOA antibodies are designed to achieve SAMHSA-compatible sensitivity cutoffs when formulated in standard competitive immunoassay configurations.
Four monoclonal antibodies targeting the most commonly screened drugs of abuse, with reference to internationally recognized screening cutoff concentrations.
| Drug Target | Analyte Detected | Assay Format | SAMHSA Cutoff | Sample Type | Key Applications |
|---|---|---|---|---|---|
| THC (Cannabis) | THC-COOH (urine metabolite) | Competitive LFA / ELISA | 50 ng/mL | Urine | Workplace testing, forensics, clinical |
| AMP (Amphetamine) | Amphetamine + Methamphetamine | Competitive LFA / ELISA | 500 ng/mL | Urine | Workplace testing, clinical toxicology |
| MOP (Morphine/Opiates) | Morphine, Codeine, 6-MAM | Competitive LFA / ELISA | 300–2,000 ng/mL | Urine | Pain management, ER toxicology |
| MTD (Methadone) | Methadone + EDDP metabolite | Competitive LFA / ELISA | 300 ng/mL | Urine | OAT monitoring, forensics |
SAMHSA cutoffs are reference values. Actual test sensitivity is set by antibody-hapten conjugate formulation and should be validated for each LFA configuration. Contact info@sekbio.com for technical support.
High-affinity, hapten-specific antibodies for competitive LFA development at SAMHSA-compatible cutoffs across all four major DOA classes.
Sekbio's THC antibody is optimized for detection of THC-COOH (11-nor-9-carboxy-THC), the primary cannabis metabolite excreted in urine for days to weeks after cannabis use. This is the correct target for urine drug screening (not Δ9-THC itself, which is primarily a blood marker of active intoxication). The antibody is formulated for competitive LFA at the SAMHSA cutoff of 50 ng/mL THC-COOH in urine. Cannabis is the most widely used illicit drug globally, and THC testing is the highest-volume component of any multi-panel DOA rapid test — making high-sensitivity, high-specificity THC antibody performance a commercial priority for drug test manufacturers.
Sekbio's AMP antibody detects amphetamine in urine and is designed with defined cross-reactivity to methamphetamine, enabling use in broad-spectrum stimulant screening panels. SAMHSA's 2017 updated guidelines set the amphetamines cutoff at 500 ng/mL (reduced from 1,000 ng/mL) for both amphetamine and methamphetamine. The AMP antibody supports development of rapid tests for methamphetamine screening — particularly important in Asian markets (South Korea, Japan, Southeast Asia) where methamphetamine is the primary drug of concern — as well as MDMA/ecstasy screening panels in European workplace testing programs. Contact info@sekbio.com for cross-reactivity data with methamphetamine, MDMA, MDA, and related phenethylamines.
Sekbio's MOP (morphine) antibody is designed for broad opiate screening, with cross-reactivity to codeine and 6-monoacetylmorphine (6-MAM, the heroin-specific metabolite) in addition to morphine itself. This broad-spectrum cross-reactivity is essential for clinical opioid screening panels in emergency medicine (ER toxicology), where the goal is to detect any opioid ingestion — not a single specific opioid. The MOP antibody is validated for competitive LFA at clinical cutoffs ranging from 300 ng/mL (pain management panels) to 2,000 ng/mL (SAMHSA federal workplace panel). As the opioid crisis has expanded globally, MOP antibody demand has grown substantially in the North American, European, and Australian DOA testing markets.
Sekbio's MTD antibody enables methadone detection in urine at the standard 300 ng/mL cutoff for opioid agonist therapy (OAT) compliance monitoring programs. Methadone maintenance therapy (MMT) is the first-line pharmacological treatment for opioid use disorder (OUD) in most countries, and regular urine methadone testing is required to confirm patient compliance with prescribed methadone doses — distinguishing intended therapeutic use from diversion. The MTD antibody is designed with minimal cross-reactivity to morphine and other opioids, providing methadone-specific detection. Methadone testing rapid kits are used in addiction medicine clinics, correctional facilities, pain management programs, and forensic settings globally.
Sekbio's four DOA antibodies (THC, AMP, MOP, MTD) are designed for integration into multi-panel lateral flow drug test cassettes — the dominant commercial format for workplace and clinical DOA screening. Multi-panel LFA cassettes typically contain 5–12 drug targets in a single test strip, with each drug's competitive assay running independently in parallel on the same nitrocellulose membrane. Using a single antibody supplier for all panel components simplifies raw material qualification, batch consistency management, and regulatory documentation — key procurement considerations for IVD manufacturers producing CE-marked or FDA-cleared multi-panel DOA rapid tests. Sekbio's panel can be extended with additional drug targets as needed.
MOQ 1 mg per drug target for R&D evaluation. OEM quantities from 10 mg to gram scale available for large-volume LFA drug test manufacturing. Sekbio's ISO 13485-certified manufacturing in Shenzhen provides quality-assured DOA antibody supply for CE-marked and FDA-cleared drug test kit production. Global drug testing markets include North America (federal workplace testing mandates, SAMHSA guidelines), Europe (EN 15964, occupational safety regulations), and Asia-Pacific (methamphetamine and opioid testing mandates). Contact our team or visit our Products page for DOA antibody evaluation kits, hapten conjugate support, and multi-panel drug test development partnerships.
Competitive immunoassay antibodies for workplace drug testing, clinical toxicology, forensic screening, and opioid treatment compliance monitoring.
Pre-employment, random, post-incident, and return-to-duty drug testing programs in safety-sensitive industries (transportation, construction, healthcare, military) use multi-panel DOA rapid tests for initial urine screening, followed by GC-MS/LC-MS confirmation for positive results. U.S. federal DOT (Department of Transportation) and SAMHSA regulations mandate drug testing covering THC, cocaine, opiates, amphetamines, and PCP for employees in safety-sensitive positions. Sekbio's THC, AMP, and MOP antibodies are critical components of 5-panel and extended-panel workplace test kits. The global occupational drug testing market exceeds $3.5 billion annually, with the U.S., EU, and Australia representing the largest regulated markets for multi-panel LFA drug test kits.
Emergency department urine drug screens are performed in the evaluation of altered mental status, suspected overdose, psychiatric presentations, and trauma cases — where drug ingestion may be contributing to the patient's condition. Rapid urine drug screening panels (typically 5–10 drug targets) provide ER physicians with preliminary drug ingestion data within 5–10 minutes, guiding immediate treatment decisions (naloxone administration for opioid overdose, supportive care for stimulant toxicity). The MOP antibody's broad opiate cross-reactivity is particularly valuable for ER opioid screening, where clinical urgency requires rapid results. MTD testing is increasingly important in clinical settings due to methadone's long half-life and its distinct overdose management requirements compared to short-acting opioids.
Drug testing in criminal justice settings — probation and parole compliance monitoring, drug court programs, driving under the influence (DUI) investigations, and child protective services cases — uses DOA rapid tests as initial screening tools prior to confirmatory laboratory analysis. Forensic drug testing requires high sensitivity (to minimize false negatives) and high specificity (to minimize false positives that could result in legal consequences). Sekbio's DOA antibodies are designed with sensitivity appropriate for initial forensic screening at standard cutoff concentrations, with confirmation recommended by GC-MS or LC-MS/MS. The THC antibody is particularly relevant for DUI/DUID (driving under the influence of drugs) investigations as cannabis legalization expands globally.
Methadone maintenance therapy (MMT) and buprenorphine OAT programs require regular urine drug testing to monitor patient compliance — confirming that prescribed medications are being taken (rather than diverted) and detecting co-use of illicit drugs (heroin, methamphetamine) that would indicate treatment instability. Sekbio's MTD antibody enables methadone-specific rapid test development for clinic-based urine testing. The MOP antibody (for heroin/morphine co-use detection) and AMP antibody (for methamphetamine co-use detection) complement MTD testing in comprehensive OAT monitoring panels. With opioid use disorder affecting an estimated 40 million people globally, OAT compliance testing represents a large and growing application for multi-analyte DOA rapid tests. Contact our team for OAT panel development support.
Technical and commercial questions from IVD R&D engineers developing DOA rapid test kits and competitive immunoassay panels.
DOA antibodies work through competitive inhibition: free drug in urine competes with drug-BSA/KLH conjugate (immobilized on nitrocellulose membrane) for binding to anti-drug antibody. If drug concentration is below the cutoff, most antibody binds the conjugate → visible test line (negative result). If drug concentration exceeds cutoff, most antibody is occupied by free drug → weak or absent test line (positive result). This inverse signal-concentration relationship is opposite to sandwich LFA. Cutoff sensitivity is adjusted by the ratio of antibody to conjugate in the test formulation.
Sekbio's DOA panel covers: THC (cannabis/marijuana — urine metabolite THC-COOH, SAMHSA cutoff 50 ng/mL); AMP (amphetamine with methamphetamine cross-reactivity, SAMHSA cutoff 500 ng/mL); MOP (morphine/opiates — morphine, codeine, 6-MAM, SAMHSA cutoff 300–2,000 ng/mL); MTD (methadone, cutoff 300 ng/mL). These four targets constitute the core DOA panel for workplace, clinical, and forensic testing. Contact info@sekbio.com if you need additional drug targets (cocaine/BZE, PCP, benzodiazepines, fentanyl, buprenorphine, etc.).
Sekbio's MOP antibody is designed for detection of morphine, codeine, and heroin metabolites (6-MAM). It typically shows limited cross-reactivity with synthetic opioids such as fentanyl, oxycodone, and hydrocodone — which have distinct chemical structures from morphine. For fentanyl screening, a dedicated anti-fentanyl antibody is required (fentanyl has become a major DOA concern due to its prevalence in illicit drug supplies). Contact info@sekbio.com to inquire about fentanyl, oxycodone, buprenorphine, and other extended opioid panel antibody availability.
Standard DOA THC antibodies are designed to detect THC-COOH (carboxy-THC, the primary cannabis metabolite) at the SAMHSA 50 ng/mL cutoff. CBD (cannabidiol) is a distinct cannabinoid compound structurally different from THC and THC-COOH. Well-designed anti-THC antibodies show minimal cross-reactivity with CBD at normal CBD supplement consumption levels. However, high-dose CBD users may have trace THC-COOH levels from CBD product contamination, which could trigger a positive DOA test. Cross-reactivity with CBD, CBN, and other cannabinoids should be validated for each specific antibody. Contact info@sekbio.com for detailed cross-reactivity data.
MOQ is 1 mg per antibody for R&D evaluation. OEM quantities from 10 mg to gram scale available for LFA manufacturing. Hapten-BSA/OVA/KLH conjugates (for membrane coating/competitive antigen) may also be available — contact info@sekbio.com for conjugate availability. Sekbio's ISO 13485-certified manufacturing supports CE-marked and FDA-cleared drug test kit development. We serve DOA rapid test manufacturers globally, including North America, Europe, Asia-Pacific, and Latin America.
Primary sample type: urine (the standard matrix for DOA screening worldwide, per SAMHSA, EU, and WHO guidelines). Urine provides high drug and metabolite concentrations, is non-invasive, and is the regulatory gold standard for workplace and forensic drug testing. Secondary applications: oral fluid (saliva) — requires antibodies optimized for blood/saliva drug concentrations rather than urine metabolite concentrations (THC parent compound is the target in saliva, not THC-COOH). Hair and sweat patch testing require additional matrix-specific validation. Contact info@sekbio.com to discuss oral fluid DOA antibody requirements and cross-format validation support.
Request DOA antibody evaluation kits, hapten conjugate options, or discuss OEM multi-panel LFA drug test development with our team.